Parkinson’s disease is a nervous system disease associated with the degeneration of the substantia grisea nuclei in the lower parts of the brain. The treatments for this disease may be planned in three groups:
The ﬁrst is the protection of the patient from being introverted and being isolated from the society, by means of useful activities and mental activities.
The second is the surgical treatment, which is employed to reduce the suﬀering of the patient and consists of the destruction of the diseased region with electricity or alcohol. The shaking usually improves following the surgical treatment, but no visible improvement occurs in the rigidity and the motions.
The third treatment, which is today considered to be the primary treatment for Parkinson’s disease, is the drug treatment. In the brain, there is a certain balance between acetylcholine, which increases the ability of the nerve cells to be stimulated, and dopamine, which performs the action opposite to that of acetylcholine. In the case of Parkinson’s disease, this balance has been disturbed in favor of acetylcholine and the dopamine deﬁcit should be replaced. The synthetic dopamine is not able to cross the barrier between the blood and the brain. This problem was solved upon the discovery of L-Dopa, which converts into dopamine after crossing the blood-brain barrier. For the treatment, L-Dopa is administered at doses gradually increased until the dose at which the symptoms disappear. In addition, amantadine, an anti-viral drug, and bromocriptine, with similar action to dopamine, may be added to the treatment in order to support L-Dopa. The studies on the brain tissue transplantation are also currently in progress. The basis of this approach is not the transplantation of the brain, and it involves the transplantation of a small portion producing dopamine from a fetus that has just died to the patient’s brain.
The treatments according to the state of the art employed for the treatment of Parkinson’s disease involve the use of l-dopa or dopamine receptor agonists. The use of synthetic L-dopa leads to neurotoxic eﬀect and loses functionality in the medium term. Also, the dopamine receptor agonists become inactive when the receptors develop tolerance.
As a result, the presence of the need for a composition formed for the use of methylsalidroside and colforsin derivatives in the treatment of Parkinson’s disease and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.
Inventors: Erdal Can Alkoçlar & Metehan Yeşil
Part 1: (click to download)
Part 2: (click to download)